Evidence map›Paper›PMID 40151112›Full record

ArticleJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2025

Yishen Tongluo formula ameliorates kidney injury modulating inflammation and apoptosis in streptozotocin-induced diabetic kidney disease mice.

Yuan Jiayao, W U Suhui, Meng Yufan, L I Hanbing, L I Genlin, X U Jiangyan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yuan JiayaoClinical Pharmacology Teaching and Research Office, School of Medicine, Henan University of Chinese Medicine, Zhengzhou 450000, China.
W U SuhuiClinical Pharmacology Teaching and Research Office, School of Medicine, Henan University of Chinese Medicine, Zhengzhou 450000, China.
Meng YufanSchool of Pharmacolog, Henan Medical College, Zhengzhou 450000, China.
L I HanbingClinical Pharmacology Teaching and Research Office, School of Medicine, Henan University of Chinese Medicine, Zhengzhou 450000, China.
L I GenlinClinical Pharmacology Teaching and Research Office, School of Medicine, Henan University of Chinese Medicine, Zhengzhou 450000, China.
X U JiangyanAcademy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou 450000, China.

Funding

Key Science and Technology Projects of Henan Province: Research on Innovative Drug Cooperation of Traditional Chinese Medicine Yishen Tongluo Concentrated Pills 221111520300Key scientific and technological projects of Henan province: Study on the Pharmacodynamic Mechanism of Yishen Tongluo Formula in Treatment of Diabetes Kidney Disease based on the Interaction Regulation of Protein Phosphorylation and Acylation Modification to WU Suhui 212102310347National Key Research and Development Plan: Evidence-Based Evaluation and Therapeutic Mechanism Cooperation Study of Yishen Tongluo Formula for Preventing Diabetes Kidney Disease (Phase 3) 2020YFE0201800National Natural Science Foundation of China: the Mechanism of Yishen Tongluo Formula Intervention in Diabetic Kidney Disease based on (Yin-Yang-1/Nuclear Factor Erythroid 2-Related Factor 2 Mediated Endothelial Podocyte Interaction Response to XU Jiangyan 82474495
6 · The paper itself

Abstract

objectiveTo investigate the effect and mechanism of Yishen Tongluo formula (, YSTLF) in streptozotocin-induced diabetic kidney disease mice (DKD) mice.

methodsThirty Institute of Cancer Research mice (specific pathogen free, SPF grade) were divided into five groups (

resultsIn DKD mice, fasting blood glucose, C-peptide, 24-hour urine protein (UP) levels, and renal damage were elevated, accompanied by increased inflammation and apoptosis. YSTLF significantly reduced 24-hour UP and C-peptide levels and improved kidney and liver function in DKD mice. YSTLF also mitigated glomerular hypertrophy, basement membrane thickening, and podocyte foot process effacement. It upregulated the expression of the podocyte marker podocalyxin. Furthermore, YSTLF alleviated inflammation and apoptosis, likely by reducing the overexpression of monocyte chemoattractant protein (MCP-1), Bax, and Caspase-3 in the kidneys of DKD mice.

conclusionsThese findings suggest that YSTLF ameliorates kidney injury by modulating the expression of inflammatory cytokine MCP-1 and the Bax/Caspase-3 apoptosis pathway, providing a potential therapeutic approach for DKD.

Indexed as

ApoptosisDiabetic NephropathiesDrugs, Chinese HerbalKidneyAnimalsChemokine CCL2HumansMaleMiceStreptozocinChemokine CCL2Drugs, Chinese HerbalStreptozocinyishenapoptosisdiabetic nephropathiesinflammationYishen Tongluo formula

Identifiers

PMID40151112
PMCPMC11955756

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.